Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Royalty Pharma said it is 'really excited' about the outlook for royalty financing, indicating a constructive view despite a changing macro backdrop. The discussion also highlighted potential opportunities to acquire royalties from alternative and private credit holders that may no longer want them, though the article provides no transaction specifics or financial figures.

Analysis

The key implication is that the royalty market is likely to become more seller-friendly for a high-quality buyer set, not because capital is scarce, but because alternative capital has mispriced duration and optionality. That creates a widening spread between “financially engineered” royalty assets coming out of private/credit hands and the long-duration, clinically diversified assets that public royalty buyers can underwrite more cleanly. In practice, Royalty Pharma should see less competition from non-core holders on the low end of the quality spectrum, while still retaining pricing power on premier assets.

Second-order, this environment can improve deal flow more than it improves headline returns: stressed or strategic sellers usually surface when their internal hurdle rates shift, and that can increase proprietary access before auctions clear. The risk is that competition for the best paper stays intense enough to compress yields, so the upside comes from selectivity and scale, not blanket expansion. If management is right that they are seeing opportunity now, the catalyst is likely months, not days, and will show up first in transaction cadence rather than reported earnings.

The contrarian miss is that investors may focus on “cheapening” as a positive for RPRX without asking whether the market is offering them longer-dated but lower-quality assets with hidden binary risk. Royalty portfolios look safe until concentration, patent life, or clinical dependencies surface, so a rising supply of secondary royalties could actually widen dispersion inside the asset class. That favors the incumbent with underwriting depth and a low cost of capital, while punishing smaller buyers that rely on leverage or need to mark assets more frequently.

Key Decisions for Investors

• Overweight RPRX on a 3-6 month horizon; use any pullback from conference-driven optimism to build a core long, targeting a rerating as transaction flow improves. Risk/reward is attractive if the market begins to price in accelerating deployment without a material increase in leverage.
• Pair trade: long RPRX / short a levered private-credit or alt-asset vehicle with royalty exposure, to express the widening quality spread between institutional buyers and forced sellers. The thesis is that lower-quality royalty inventory will clear at discounts before premium assets do.
• Sell upside volatility via covered calls on RPRX over the next 1-2 quarters if implied volatility spikes into deal announcements. The market may overpay for near-term catalyst optionality while underestimating the slower cadence of monetization.
• Avoid chasing smaller royalty platforms that need external financing to compete in acquisitions; their underwriting edge is weaker and any asset-quality surprise will hit harder if funding conditions tighten. This is a relative short, not necessarily an absolute short.
• Set a catalyst watch for 1H26 deal announcements and any commentary on seller mix; if the company starts taking larger checks from secondary holders, that is confirmation the opportunity set is improving and could justify adding on strength.